Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Mark E. Bunnage reported sales of common stock under Rule 144. The filing lists four dispositions: 12/29/2025 — 23 shares for $10,649.00; 02/11/2026 — 2,021 shares for $930,529.03; 02/17/2026 — 2,437 shares for $1,192,814.02; and 02/18/2026 — 1,182 shares for $559,889.76. The transactions are reported as sales by the holder and include a separate 620-share restricted stock vesting on 02/24/2026 noted as compensation.
Vertex Pharmaceuticals reported Form 144 sales by a reporting person. The excerpt lists sales by E Morrey Atkinson of 1,751 common shares on 02/11/2026 for $806,212.93, 2,031 common shares on 02/17/2026 for $994,093.26, and 817 common shares on 02/18/2026 for $386,996.56. The filing also shows 668 common shares tied to a restricted stock vesting on 02/24/2026.
Vertex Pharmaceuticals submitted a Rule 144 notice reporting a sale of 58,613 shares on 02/19/2026 for $27,479,575.26.
The filing also lists restricted stock vesting of 1,846 common shares tied to 02/24/2026 described as compensation, and identifies Fidelity Brokerage Services LLC as the broker.
Vertex Pharmaceuticals reported insider sales by Jonathan P. Biller of Common stock under Rule 144. The filing lists individual transactions including 347 shares on 12/03/2025 for $155,803.00, 1,925 shares on 02/11/2026 for $886,327.75, 988 shares on 02/13/2026 for $493,012.00, 2,476 shares on 02/17/2026 for $1,211,902.96, and 1,244 shares on 02/18/2026 for $589,257.92.
The report shows these dispositions were made from holdings registered with Fidelity Brokerage Services LLC and includes a separate entry for 945 shares vested on 02/24/2026 as restricted stock vesting.
Vertex Pharmaceuticals executive Amit Sachdev reported option exercises and share sales. On February 19, 2026, he exercised stock options covering 23,479 shares at a price of $155.57 per share and 25,026 shares at $187.53 per share, converting them into common stock.
On the same date, he sold a total of 58,613 shares of common stock in multiple open-market transactions at prices ranging from approximately $463.91 to $471.43, under a company-approved Rule 10b5-1 trading plan entered into on November 18, 2025. Following these transactions, he held 58,934 shares directly, plus 882 shares in a 401(k) and 9,301 shares held in a trust.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, Chief Operating Officer and Chief Financial Officer, reported two stock transactions involving the company’s common stock. He received a grant of 7,365 restricted stock units, described as an award that vests in installments beginning on February 20, 2027. This award increased his directly held shares to 51,080 immediately after the grant.
On the same date, Wagner had 2,294 shares of common stock disposed of at $483.75 per share in a transaction coded as a tax-withholding disposition to satisfy tax obligations by delivering securities. After this withholding transaction, his direct ownership stood at 48,786 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported a mix of stock transactions involving company common shares. She received a grant of 5,789 shares as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,294 shares were disposed of to cover tax obligations at a price of $483.75 per share. She also executed open-market sales of 609 shares at $489.46 per share and 368 shares at $473.68 per share, made under a company-approved Rule 10b5-1 trading plan entered on August 21, 2025. Following these transactions, she directly owned 48,650 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported mixed equity transactions. He received a grant of 5,789 shares of common stock as a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 2,140 shares were disposed of at $483.75 per share to satisfy tax withholding obligations, leaving him with 69,042 shares held directly, plus additional common stock held indirectly through a 401(k) plan and a trust.
Vertex Pharmaceuticals executive Duncan McKechnie reported a mixed Form 4 transaction involving company stock. He acquired 4,962 shares of common stock on February 17, 2026 through a restricted stock unit award that will vest in installments beginning on February 20, 2027. On the same date, 1,148 shares were disposed of at $483.75 per share to cover tax obligations by delivering shares, leaving him with 23,342 shares of common stock held directly.
Vertex Pharmaceuticals (common stock) reported a Form 144 notice showing proposed sales of common shares by an affiliate on various dates in 2026. The filing lists multiple lots tied to restricted stock vesting and option exercises, including 3,187; 4,318; 2,603; 23,479; and 25,026 shares on 02/10/2026, 02/13/2026, 02/17/2026, and 02/19/2026.
The notice names Fidelity Brokerage Services LLC and references NASDAQ; it reports the security type as Common and identifies several sale methods (vested restricted stock and option-related cash transactions). This is a routine affiliate sale notice under Rule 144; timing and exact sale mechanics depend on the holder's execution of the listed transactions.